Özet:

Aim: Immune thrombocytopenia (ITP) is the most common cause of acquired thrombocytopenia in childhood. It is an autoimmune disease that is elicited by the destruction of platelets with autoantibodies. We aimed in this study to investigate the clinical features of the disease and provide insight into how the treatment method is determined accordingly. It is also intended to examine and compare the treatment responses. Materials and Methods: Between January 2013 and December 2018, a total of 80 patients diagnosed as ITP, at the Pediatric Hematology Outpatient Clinic were enrolled in the study. During the study period, we provided to record data of all patients thoroughly. We finally compared the results of those undergoing appropriate medical therapy statistically after the exclusion of the causes of secondary thrombocytopenia. Results: The mean age of the patients was 5 ± 2.3 years; the ratio of females to males was found to be 1 to 2. Among the most common complaints were that ecchymosis (63.7%) ranked first, followed by petechiae (%20). Four (5%) patients received no treatment. Methylprednisolone, IVIG, and dexamethasone were given in 49 (61.2%), 17 (21.2%), and 8 (10%) patients, respectively. Both of methylprednisolone and IVIG were given to only 2 (2.5%) patients. Conclusion: The ITP patients receiving IVIG have been found to progress to chronicity more than those receiving methylprednisolone. Our study also presents knowledge to be able to predict the development of chronicity in ITP.

Anahtar Kelimeler: